CellSource Co

CellSource Co EBITDA Growth YoY

The Year-over-Year EBITDA Growth of CellSource Co (4880.T) as of Oct 27, 2026 is -10.12 %. In the previous year, Year-over-Year EBITDA Growth was -85.60 % — a change of -88.18% (higher).

EBITDA Growth YoY

-10.12 %

YoY

-88.18%

Last updated:

Year-over-Year EBITDA Growth of CellSource Co is 2025 -10.12 % . Year-over-Year EBITDA Growth of CellSource Co was 2024 -85.60 % . It decreases by -88.18% higher compared to the previous year.

The CellSource Co EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2018
86.97 JPY
Jan 1, 2019
12.01 JPY
Jan 1, 2020
26.94 JPY
Jan 1, 2021
137.37 JPY
Jan 1, 2022
57.57 JPY
Jan 1, 2023
-18.71 JPY
Jan 1, 2024
-85.60 JPY
Jan 1, 2025
-10.12 JPY
The CellSource Co EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
-10.12 %-88.18%
-85.60 %+357.57%
-18.71 %-132.50%
57.57 %-58.10%
137.37 %+409.92%
26.94 %+124.40%
12.01 %-86.20%
86.97 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

Year-over-Year EBITDA Growth of CellSource Co is -10.12 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth CellSource Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's CellSource Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — CellSource Co

All Key Metrics — CellSource Co